Picroside II as a Potential Anti-Inflammatory Agent
Open accessAbstract
Inflammation, as a basic pathological process, is critically implicated in the pathogenesis and progression of numerous diseases. Picrorhizae rhizoma is a type of traditional Chinese medicine with prominent anti-inflammatory effect. And picroside II, a representative iridoid compound, is the major bioactive constituent of Picrorhizae rhizoma. Over recent decades, picroside II has garnered extensive research interest owing to its remarkable pharmacological efficacy. Accumulating evidence has validated that picroside II exerts significant anti-inflammatory effects in the prevention and treatment of various systemic diseases. This review comprehensively summarizes and updates the latest research advances of picroside II, systematically elaborating its anti-inflammatory molecular mechanisms, pharmacokinetic profiles, and safety evaluation characteristics. The integrated data and analyses in this review aim to provide solid theoretical support, reliable evidence, and novel insights for the in-depth mechanism research, rational medicinal development, and future clinical translation and application of picroside II.
AI snapshot
Written from the paper’s full text.
TL;DR
This review summarizes preclinical evidence that picroside II, the major bioactive iridoid of Picrorhizae rhizoma, exerts broad anti-inflammatory and organ-protective effects through NF-κB, HMGB1-RAGE, MAPK, JAK-STAT, cytokine, and oxidative-stress pathways. It concludes that picroside II has a favorable preclinical pharmacokinetic and safety profile but lacks sufficient human data for clinical translation.
Key findings
- Picroside II inhibits multiple inflammatory pathways, including NF-κB, HMGB1-RAGE/TLR2/TLR4, MAPK (p38, ERK1/2, JNK), and JAK2/STAT3, and reduces pro-inflammatory mediators such as IL-1β, IL-6, and TNF-α across cerebral, cardiovascular, lung, kidney, intestinal, and liver disease models.
- Pharmacokinetic data show low absolute oral bioavailability and formulation-dependent absorption; 13 metabolites were identified after oral dosing in rats via four main pathways, and hepatic glucosylation intrinsic clearance was 10.6-fold, 6.0-fold, and 2.3-fold higher in rats, mice, and dogs than in humans, respectively. In dogs, intravenous picroside II had an average elimination half-life below 30 min.
- Safety studies report no obvious acute toxicity in mice and no cumulative toxicity in beagle dogs at 10–30 mg/kg daily oral doses over 6 months. Drug-interaction data show ketoconazole increased picroside II AUC by 2.1-fold, while rifampicin reduced it by 68%.
- For cerebral ischemic injury, the optimal therapeutic regimen was reported as intraperitoneal injection of 10–20 mg/kg picroside II at 1.5–2.0 h after ischemia onset.
Methods
- Narrative review synthesizing preclinical studies on picroside II’s anti-inflammatory mechanisms, pharmacokinetics, and safety evaluation.
- Evidence cited includes in vitro cell experiments, rodent disease models, and dog pharmacokinetic/toxicity studies; tables summarize pharmacokinetic parameters and anti-inflammatory effects.
- No systematic search strategy, inclusion criteria, or meta-analysis is described in the paper.
Limitations
- The paper states that most evidence is from in vitro and rodent models, with limited large-animal or clinical validation; human pharmacokinetics, optimal dose, and drug-interaction characteristics remain largely uncharacterized.
- The paper states that direct molecular targets and precise upstream regulatory mechanisms of picroside II are not fully elucidated, and heterogeneity in experimental designs reduces comparability and reproducibility.
- The paper notes that safety conclusions may be limited by dosage, administration period, and animal species; evident from the text, the review is narrative rather than systematic, so study selection and quality assessment are not formally reported.
Model-written summary. Check it against the paper before relying on it.
Integrity signals
Registry
Cites
Statistics
Claims the paper makes
33 of 79 cited sources checked · 16 supported · 0 flagged · accuracy not yet measured
- Premisecitation
Picrorhizae rhizoma is a traditional Chinese medicine with prominent anti-inflammatory effect.
“Picrorhizae rhizoma is a type of traditional Chinese medicine with prominent anti-inflammatory effect.”
Quote in the paperSubstantial claim1 of 3 sources checked- cites [6] Ma, 2020, The beneficial pharmacological effects and potential mechanisms of picroside II: Evidence of its benefits from in vitro and in vivo, Biomed. Pharmacother. source
- cites [10] Guo, 2020, Chemical components, pharmacological actions, and clinical applications of rhizoma picrorhizae, Phytother. Res. source
- cites [12] Dong, 2021, Hepatoprotective activity assessment of amino acids derivatives of picroside I and II, Chem. Biol. Drug Des. source
- Premisecitation
Picroside II inhibits the JAK-STAT pathway in a pentobarbital-induced severe acute pancreatitis rat model.
“Piao et al. [65] demonstrated that picroside II could inhibit the JAK-STAT pathway in a pentobarbital-induced severe acute pancreatitis (SAP) rat model.”
Quote in the paperSubstantial claim1 of 1 sources checked- cites [65] Piao, 2021, Picroside II improves severe acute pancreatitis-induced hepatocellular injury in rats by affecting JAK2/STAT3 phosphorylation signaling, BioMed Res. Int. source
Results §3.8 reports that picroside II reduced p-JAK2 and p-STAT3 protein levels in the rat model, supporting the pathway claim. But Methods §2.2 says pentobarbital sodium was used for anesthesia and SAP was induced with sodium taurocholate, not pentobarbital. The Discussion calls the model established ‘using Pentobarbital sodium,’ but the procedural description distinguishes the anesthetic from the inducing agent. (LLM, conf=0.88)
Experimental — accuracy not yet measured
- Premisecitation
The optimal therapeutic dose and time window for cerebral ischemic injury is intraperitoneal injection of 10-20 mg/kg picroside II at 1.5-2.0 h after ischemia onset.
“On the basis of a therapeutic window and dose-finding rationale, the optimal therapeutic dose and time window for cerebral ischemic injury were determined as intraperitoneal injection of 10–20 mg/kg picroside II at 1.5–2.0 h after ischemia onset [83].”
Quote in the paperSubstantial claim1 of 1 sources checked- cites [83] Zhao, L., Guo, Y., Ji, X., and Zhang, M. (2014). The neuroprotective effect of picroside II via regulating the expression of myelin basic protein after cerebral ischemia injury in rats. BMC Neurosci., 15. source
- Premisecitation
Picroside II inhibits HMGB1-RAGE in rats with myocardial ischemia-reperfusion injury.
“Li et al. [18] demonstrated that picroside II inhibits HMGB1-RAGE in rats with myocardial ischemia–reperfusion (I/R) injury.”
Quote in the paperSubstantial claim1 of 1 sources checked- cites [18] Li, 2016, Picroside II protects myocardium from ischemia/reperfusion-induced injury through inhibition of the inflammatory response, Exp. Ther. Med. source
- Premisecitation
Picroside II markedly decreased GATA3 and Th2 cytokine expression in differentiating Th2 cells.
“Picroside II markedly decreased GATA3 and Th2 cytokine expression in differentiating Th2 cells, thereby protecting against allergic asthma by suppressing GATA3 expression and Th2 cytokine bias [68].”
Quote in the paperSubstantial claim1 of 1 sources checked- cites [68] Choi, J., Choi, B.K., Kim, J.S., Lee, J.W., Park, H.A., Ryu, H.W., Lee, S.U., Hwang, K.W., Yun, W.K., and Kim, H.C. (2016). Picroside II attenuates airway inflammation by downregulating the transcription factor GATA3 and Th2-related cytokines in a mouse model of HDM-induced allergic asthma. PLoS ONE, 11. source
- Premisecitation
The protective effect of picroside II on ischemia-reperfusion-induced myocardial injury is partly associated with inhibiting the inflammatory response by suppressing the HMGB1-RAGE/TLR2/TLR4-NF-κB signaling pathway.
“Li et al. [18] reported that the protective effect of picroside II on I/R-induced myocardial injury is partly associated with inhibiting the inflammatory response by suppressing the HMGB1-RAGE/TLR2/TLR4-NF-κB signaling pathway.”
Quote in the paperSubstantial claim1 of 1 sources checked- cites [18] Li, 2016, Picroside II protects myocardium from ischemia/reperfusion-induced injury through inhibition of the inflammatory response, Exp. Ther. Med. source
- Interpretationreasoning
Picroside II exerts significant anti-inflammatory effects in the prevention and treatment of various systemic diseases.
“Accumulating evidence has validated that picroside II exerts significant anti-inflammatory effects in the prevention and treatment of various systemic diseases.”
Quote in the paperSubstantial claim - Premisecitation
Picroside II does not cause significant toxic reactions even after prolonged use.
“Recent chronic toxicity studies have shown that picroside II does not cause significant toxic reactions even after prolonged use [22].”
Quote in the paperSubstantial claim0 of 1 sources checked- cites [22] Upadhyay, 2013, Comparative pharmacokinetic profiles of picrosides I and II from kutkin, Picrorhiza kurroa extract and its formulation in rats, Fitoterapia source
- Premisecitation
Picroside II exhibits potent hepatoprotective effects due to its high hepatic uptake.
“Picroside II exhibits potent hepatoprotective effects due to its high hepatic uptake [13].”
Quote in the paperNot a substantial claim0 of 1 sources checked- cites [13] Zhu, 2015, A pre-clinical pharmacokinetic study in rats of three naturally occurring iridoid glycosides, picroside-I, II, and III, using a validated simultaneous HPLC-MS/MS assay, J. Chromatogr. B Anal. Technol. Biomed. Life Sci. source
- Interpretationreasoning
Picroside II exhibits multiple anti-inflammatory mechanisms.
“From the above discussion, it can be concluded that picroside II exhibits multiple anti-inflammatory mechanisms.”
Quote in the paperSubstantial claim - Premisecitation
Picroside II downregulates LPS-induced phosphorylated p65 relative to total p65 and the levels of NLRP3, caspase-1, and IL-1β in macrophages.
“The authors reported that picroside II downregulated the LPS-induced expression of phosphorylated p65 (p-p65) relative to total p65, as well as the levels of key inflammatory mediators including NOD-like receptor protein 3 (NLRP3), caspase-1, and interleukin 1β (IL-1β) in macrophages [40].”
Quote in the paperSubstantial claim0 of 1 sources checked- cites [40] Yao, 2022, Picroside II alleviates dss-induced ulcerative colitis by suppressing the production of NLRP3 inflammasomes through NF-κB signaling pathway, Immunopharmacol. Immunotoxicol. source
- Interpretationreasoning
Picroside II acts as a multi-system protective agent.
“In summary, picroside II acts as a multi-system protective agent, and existing research has mainly focused on its anti-inflammatory, antioxidant, and anti-apoptotic properties.”
Quote in the paperSubstantial claim - Premisecitation
Picroside II modulates the activity of multiple CYP enzymes in human and rat liver microsomes.
“Their results indicated that picroside II modulates the activity of multiole CYP enzymes, warranting careful monitoring when picroside II is co-administered with conventional drugs.”
Quote in the paperNot a substantial claim0 of 1 sources checked- cites [28] Zhou, 2023, Evaluation potential effects of picroside II on cytochrome p450 enzymes in vitro and in vivo, J. Ethnopharmacol. source
- Premisecitation
Picroside II can suppress MAPK phosphorylation.
“Accumulating evidence indicates that picroside II can suppress MAPK phosphorylation.”
Quote in the paperSubstantial claim - Premisecitation
The absorption rate and extent of picroside II after oral administration are highly formulation-dependent.
“The absorption rate and extent of picroside II after oral administration are highly formulation-dependent [22].”
Quote in the paperNot a substantial claim0 of 1 sources checked- cites [22] Upadhyay, 2013, Comparative pharmacokinetic profiles of picrosides I and II from kutkin, Picrorhiza kurroa extract and its formulation in rats, Fitoterapia source
- Interpretationnone given
Picroside II exhibits high sensitivity toward inflammatory responses.
“Our review indicates that picroside II exhibits high sensitivity toward inflammatory responses (Table 2) (see Figure 5).”
Quote in the paperNot a substantial claim - Premisecitation
Picroside II significantly inhibits IBDV replication in a dose-dependent manner for at least 72 h.
“Picroside II (5–30 μM) shows promising anti-infectious bursal disease (IBDV) activity and significantly inhibits IBDV replication in a dose-dependent manner for at least 72 h [112].”
Quote in the paperNot a substantial claim0 of 1 sources checked- cites [112] Zhang, 2024, Picroside II disrupts IBDV replication via targeting VP1 polymerase, Vet. Microbiol. source
- Interpretationreasoning
Picroside II has a high degree of safety for short-term use.
“This suggests that picroside II has a high degree of safety for short-term use.”
Quote in the paperSubstantial claim - Interpretationcitation
Picroside II has shown excellent short-term safety in multiple standardized preclinical models.
“In acute toxicity studies, picroside II has shown excellent short-term safety in multiple standardized preclinical models.”
Quote in the paperNot a substantial claim - Premisecitation
Picroside II (5-30 μM) shows anti-infectious bursal disease (IBDV) activity.
“Picroside II (5–30 μM) shows promising anti-infectious bursal disease (IBDV) activity and significantly inhibits IBDV replication in a dose-dependent manner for at least 72 h [112].”
Quote in the paperNot a substantial claim0 of 1 sources checked- cites [112] Zhang, 2024, Picroside II disrupts IBDV replication via targeting VP1 polymerase, Vet. Microbiol. source
- Premisecitation
In dogs, intravenous picroside II was rapidly eliminated from plasma, with an average elimination half-life below 30 min.
“In dogs, intravenous picroside II was rapidly eliminated from plasma, with an average elimination half-life below 30 min [24].”
Quote in the paperNot a substantial claim0 of 1 sources checked- cites [24] Yang, 2005, Determination of picroside II in dog plasma by HPLC and its application in a pharmacokinetics study, Biomed. Chromatogr. source
- Premisenone given
Picroside II exhibits low absolute oral bioavailability.
“Picroside II exhibits low absolute oral bioavailability.”
Quote in the paperNot a substantial claim - Interpretationreasoning
Inhibition of NF-κB signaling represents one potential mechanism underlying the alleviation of chronic inflammation.
“Therefore, inhibition of NF-κB signaling represents one potential mechanism underlying the alleviation of chronic inflammation.”
Quote in the paperSubstantial claim - Premisecitation
The intrinsic clearance rates of hepatic glucosylation of picroside II in rats, mice, and dogs are 10.6-fold, 6.0-fold, and 2.3-fold higher than in humans, respectively.
“Li et al. [29] confirmed that the intrinsic clearance rates of hepatic glucosylation of picroside II in rats, mice, and dogs were 10.6-fold, 6.0-fold, and 2.3-fold higher than those in humans, respectively.”
Quote in the paperNot a substantial claim0 of 1 sources checked- cites [29] Li, 2011, Assessment of udp-glucuronosyltransferase catalyzed formation of picroside II glucuronide in microsomes of different species and recombinant ugts, Xenobiotica source
- Premisecitation
Picroside II remained stable in rat blood over short-term (6 h) and long-term (30 days) periods in different preparations.
“Stability studies confirmed that picroside II remained stable in rat blood over short-term (6 h) and long-term (30 days) periods in different preparations [22].”
Quote in the paperNot a substantial claim0 of 1 sources checked- cites [22] Upadhyay, 2013, Comparative pharmacokinetic profiles of picrosides I and II from kutkin, Picrorhiza kurroa extract and its formulation in rats, Fitoterapia source
- Premisecitation
Picroside II metabolism is mainly mediated by the hepatic CYP450 enzyme system.
“Its metabolism is mainly mediated by the hepatic CYP450 enzyme system [28].”
Quote in the paperSubstantial claim0 of 1 sources checked- cites [28] Zhou, 2023, Evaluation potential effects of picroside II on cytochrome p450 enzymes in vitro and in vivo, J. Ethnopharmacol. source
- Premisecitation
Co-administration with the CYP3A inducer rifampicin reduced picroside II AUC by 68%.
“Co-administration with the strong CYP3A inhibitor ketoconazole increased picroside II plasma exposure (AUC) by 2.1-fold, while the CYP3A inducer rifampicin reduced its AUC by 68% [28].”
Quote in the paperSubstantial claim0 of 1 sources checked- cites [28] Zhou, 2023, Evaluation potential effects of picroside II on cytochrome p450 enzymes in vitro and in vivo, J. Ethnopharmacol. source
- Interpretationnone given
Available pharmacokinetic data for picroside II are mostly from small animal models.
“Second, available pharmacokinetic data are mostly from small animal models, and the absorption, metabolism, optimal therapeutic dose window, and drug interaction characteristics of picroside II in humans remain largely uncharacterized.”
Quote in the paperSubstantial claim - Premisecitation
In rats, 2.5 mg/kg bw picroside II induced CYP3A activity.
“However, in vivo rat studies confirmed that repeated administration of picroside II can bidirectionally regulate CYP450 activity: 10 mg/kg bw daily doses inhibited CYP2C6/11 activity, while 2.5 mg/kg bw doses induced CYP3A activity.”
Quote in the paperSubstantial claim0 of 1 sources checked- cites [28] Zhou, 2023, Evaluation potential effects of picroside II on cytochrome p450 enzymes in vitro and in vivo, J. Ethnopharmacol. source
- Premisecitation
Co-administration with the strong CYP3A inhibitor ketoconazole increased picroside II plasma exposure (AUC) by 2.1-fold.
“Co-administration with the strong CYP3A inhibitor ketoconazole increased picroside II plasma exposure (AUC) by 2.1-fold, while the CYP3A inducer rifampicin reduced its AUC by 68% [28].”
Quote in the paperSubstantial claim0 of 1 sources checked- cites [28] Zhou, 2023, Evaluation potential effects of picroside II on cytochrome p450 enzymes in vitro and in vivo, J. Ethnopharmacol. source
- Interpretationreasoning
The absorption, metabolism, optimal therapeutic dose window, and drug interaction characteristics of picroside II in humans remain largely uncharacterized.
“Second, available pharmacokinetic data are mostly from small animal models, and the absorption, metabolism, optimal therapeutic dose window, and drug interaction characteristics of picroside II in humans remain largely uncharacterized.”
Quote in the paperSubstantial claim - Interpretationcitation
Picroside II has a low direct drug interaction risk at conventional effective doses.
“In vitro incubation experiments with human liver microsomes showed that picroside II (0.5–200 μM) had no significant inhibitory effect on major CYP450 subtypes (CYP1A2, CYP2C9, CYP2C19, CYP2D6, CYP3A4), suggesting a low direct drug interaction risk at conventional effective doses [28].”
Quote in the paperNot a substantial claim0 of 1 sources checked- cites [28] Zhou, 2023, Evaluation potential effects of picroside II on cytochrome p450 enzymes in vitro and in vivo, J. Ethnopharmacol. source
- Premisecitation
In rats, 10 mg/kg bw daily picroside II inhibited CYP2C6/11 activity.
“However, in vivo rat studies confirmed that repeated administration of picroside II can bidirectionally regulate CYP450 activity: 10 mg/kg bw daily doses inhibited CYP2C6/11 activity, while 2.5 mg/kg bw doses induced CYP3A activity.”
Quote in the paperSubstantial claim0 of 1 sources checked- cites [28] Zhou, 2023, Evaluation potential effects of picroside II on cytochrome p450 enzymes in vitro and in vivo, J. Ethnopharmacol. source
- Interpretationreasoning
The direct molecular targets and precise upstream regulatory mechanisms of picroside II have not been fully elucidated.
“Third, current mechanistic studies mostly focus on the phenotypic regulation of inflammatory signaling pathways and mediator release, while the direct molecular targets and precise upstream regulatory mechanisms of picroside II have not been fully elucidated.”
Quote in the paperSubstantial claim - Interpretationnone given
The heterogeneity of experimental designs (e.g., differences in administration routes, doses, and disease models across studies) reduces the comparability and reproducibility of existing results on picroside II.
“In addition, the heterogeneity of experimental designs (e.g., differences in administration routes, doses, and disease models across studies) reduces the comparability and reproducibility of existing results.”
Quote in the paperSubstantial claim - Premisecitation
Repeated administration of picroside II in rats can bidirectionally regulate CYP450 activity.
“However, in vivo rat studies confirmed that repeated administration of picroside II can bidirectionally regulate CYP450 activity: 10 mg/kg bw daily doses inhibited CYP2C6/11 activity, while 2.5 mg/kg bw doses induced CYP3A activity.”
Quote in the paperSubstantial claim0 of 1 sources checked- cites [28] Zhou, 2023, Evaluation potential effects of picroside II on cytochrome p450 enzymes in vitro and in vivo, J. Ethnopharmacol. source
- Interpretationcitation
In vitro and in vivo studies have clarified the metabolic pathway and drug interaction risk of picroside II.
“In vitro and in vivo studies have clarified the metabolic pathway and drug interaction risk of picroside II.”
Quote in the paperSubstantial claim0 of 1 sources checked- cites [28] Zhou, 2023, Evaluation potential effects of picroside II on cytochrome p450 enzymes in vitro and in vivo, J. Ethnopharmacol. source
- Interpretationnone given
Current mechanistic studies mostly focus on the phenotypic regulation of inflammatory signaling pathways and mediator release.
“Third, current mechanistic studies mostly focus on the phenotypic regulation of inflammatory signaling pathways and mediator release, while the direct molecular targets and precise upstream regulatory mechanisms of picroside II have not been fully elucidated.”
Quote in the paperSubstantial claim - Interpretationnone given
Picroside II exhibits favorable preclinical safety with minimal reported toxic reactions within the effective dose range.
“Unlike conventional anti-inflammatory agents with frequent systemic adverse effects, picroside II exhibits favorable preclinical safety with minimal reported toxic reactions within the effective dose range, highlighting its potential as a promising anti-inflammatory candidate.”
Quote in the paperNot a substantial claim - Interpretationreasoning
Current research on picroside II has notable critical limitations that restrict its clinical translation.
“However, current research on picroside II has notable critical limitations that restrict its clinical translation.”
Quote in the paperSubstantial claim - Interpretationreasoning
Picroside II has a favorable overall safety profile based on existing preclinical evidence.
“Existing preclinical evidence confirms that picroside II has a favorable overall safety profile.”
Quote in the paperNot a substantial claim - Interpretationreasoning
The safety results of chronic toxicity studies may be limited by the dosage, administration period, and species of experimental animals.
“However, the results of these studies may be limited by the dosage, administration period, and species of experimental animals, and therefore more studies are needed to further confirm the safety of long-term use.”
Quote in the paperSubstantial claim - Premisecitation
In vitro human liver microsome experiments showed that picroside II (0.5-200 μM) had no significant inhibitory effect on major CYP450 subtypes (CYP1A2, CYP2C9, CYP2C19, CYP2D6, CYP3A4).
“In vitro incubation experiments with human liver microsomes showed that picroside II (0.5–200 μM) had no significant inhibitory effect on major CYP450 subtypes (CYP1A2, CYP2C9, CYP2C19, CYP2D6, CYP3A4), suggesting a low direct drug interaction risk at conventional effective doses [28].”
Quote in the paperSubstantial claim0 of 1 sources checked- cites [28] Zhou, 2023, Evaluation potential effects of picroside II on cytochrome p450 enzymes in vitro and in vivo, J. Ethnopharmacol. source
- May combine two claims. 24
- Classified as probably not a substantial claim. 5
- The quote only partly states this claim. 2
May combine two claims.
PremisecitationPicroside II has immunomodulatory effects that alleviate inflammatory damage in various diseases by regulating immune cell differentiation, activating inflammatory signaling pathways, and secreting inflammatory factors.
“Furthermore, previous studies have shown that picroside II has excellent immunomodulatory effects, which can alleviate inflammatory damage in various diseases by regulating immune cell differentiation, activating inflammatory signaling pathways, and secreting inflammatory factors [6,17,18,19].”
Quote in the paperSubstantial claim4 of 4 sources checked- cites [6] Ma, 2020, The beneficial pharmacological effects and potential mechanisms of picroside II: Evidence of its benefits from in vitro and in vivo, Biomed. Pharmacother. source
Section 5 (Anti-inflammatory effects of PII; page unavailable) reports that picroside II alleviated inflammation and improved immune function in several disease models. But the mechanisms are misstated: the review generally reports inhibition of inflammatory pathways and reduced inflammatory cytokines, not their activation or increased secretion. It does not clearly establish regulation of immune-cell differentiation as a mechanism for the reported protection. (LLM, conf=0.88)
Experimental — accuracy not yet measured - cites [17] Guo, 2010, Anti-inflammation effects of picroside 2 in cerebral ischemic injury rats, Behav. Brain Funct. source
The Results and Discussion (page unavailable) report that picroside 2 reduced TLR4, NFκB, and TNFα levels and improved outcomes in rats with cerebral ischemia–reperfusion injury, supporting an anti-inflammatory effect in that setting. They do not establish effects across various diseases or show that picroside 2 regulates immune-cell differentiation. The reported mechanism involves reduced inflammatory signaling and TNFα, not activation of the pathway or secretion of inflammatory factors. (LLM, conf=0.88)
Experimental — accuracy not yet measured - cites [18] Li, 2016, Picroside II protects myocardium from ischemia/reperfusion-induced injury through inhibition of the inflammatory response, Exp. Ther. Med. source
The Discussion reports that picroside II reduced inflammatory damage in myocardial ischemia/reperfusion injury, and the Introduction describes anti-inflammatory findings in nervous and renal injury models. But this paper reports suppression—not activation—of inflammatory signaling and decreased—not increased—production of inflammatory factors. The cited passages do not establish an effect through immune cell differentiation. (LLM, conf=0.90)
Experimental — accuracy not yet measured - cites [19] Wang, 2014, Picroside II decreases the development of fibrosis induced by ischemia/reperfusion injury in rats, Ren. Fail. source
The Discussion (page unavailable) reports reduced inflammatory-cell infiltration and lower TNF-α and IL-1β levels after picroside II treatment in rats with renal ischemia/reperfusion injury. It does not establish effects across various diseases or show that picroside II acts by regulating immune-cell differentiation, activating inflammatory signaling pathways, or causing secretion of inflammatory factors. (LLM, conf=0.88)
Experimental — accuracy not yet measured
May combine two claims.
PremisecitationPicroside II exerts protective effects on multiple organs, including the brain, heart, and kidney, primarily through anti-inflammation, anti-oxidation, and anti-apoptosis.
“It exerts protective effects on multiple organs, including the brain, heart, and kidney, primarily through various mechanisms such as anti-inflammation, anti-oxidation, and anti-apoptosis [6,17,18,19].”
Quote in the paperSubstantial claim4 of 4 sources checked- cites [6] Ma, 2020, The beneficial pharmacological effects and potential mechanisms of picroside II: Evidence of its benefits from in vitro and in vivo, Biomed. Pharmacother. source
- cites [17] Guo, 2010, Anti-inflammation effects of picroside 2 in cerebral ischemic injury rats, Behav. Brain Funct. source
The Abstract Background and Discussion support protective effects of picroside 2 in rat cerebral ischemia, involving anti-inflammatory, antioxidant, and anti-apoptotic actions. They do not establish protection of the heart or kidney by picroside 2; the kidney-related reference concerns a plant extract rather than picroside 2 specifically. Page numbers are unavailable in our copy. (LLM, conf=0.88)
Experimental — accuracy not yet measured - cites [18] Li, 2016, Picroside II protects myocardium from ischemia/reperfusion-induced injury through inhibition of the inflammatory response, Exp. Ther. Med. source
The Introduction reports protective effects in the nervous and urinary systems and in myocardial injury; the Discussion reports heart and kidney protection associated with inhibition of inflammation. The Discussion also lists anti-oxidative and anti-apoptotic properties, but does not establish that these three mechanisms are the primary basis of protection across the brain, heart, and kidney. (LLM, conf=0.85)
Experimental — accuracy not yet measured - cites [19] Wang, 2014, Picroside II decreases the development of fibrosis induced by ischemia/reperfusion injury in rats, Ren. Fail. source
The Discussion reports that Picroside II reduced fibrosis in ischemic rat kidneys and may have done so by inhibiting long-term inflammation. This supports kidney protection and an anti-inflammatory mechanism, but the paper does not establish protection of the brain or heart, or anti-oxidation and anti-apoptosis as mechanisms for those organs. (LLM, conf=0.87)
Experimental — accuracy not yet measured
May combine two claims.
PremisecitationPicroside II is a representative iridoid compound and the major bioactive constituent of Picrorhizae rhizoma.
“And picroside II, a representative iridoid compound, is the major bioactive constituent of Picrorhizae rhizoma.”
Quote in the paperSubstantial claim1 of 4 sources checked- cites [6] Ma, 2020, The beneficial pharmacological effects and potential mechanisms of picroside II: Evidence of its benefits from in vitro and in vivo, Biomed. Pharmacother. source
- cites [13] Zhu, 2015, A pre-clinical pharmacokinetic study in rats of three naturally occurring iridoid glycosides, picroside-I, II, and III, using a validated simultaneous HPLC-MS/MS assay, J. Chromatogr. B Anal. Technol. Biomed. Life Sci. source
- cites [14] Weinges, 1972, Natural products from medicinal plants. XVII. Picroside-II, a new 6-vanilloyl-catapol from Picrorhiza kurooa royle and benth, Justus Liebigs Ann. Chem. source
- cites [15] Sharma, 2021, Transcriptome profiling reveal key hub genes in co-expression networks involved in iridoid glycosides biosynthetic machinery in Picrorhiza kurroa, Genomics source
Probably not a substantial claim: may not pass S3 (load-bearing).
PremisecitationInflammation is critically implicated in the pathogenesis and progression of numerous diseases.
“Inflammation, as a basic pathological process, is critically implicated in the pathogenesis and progression of numerous diseases.”
Quote in the paperNot a substantial claim4 of 5 sources checked- cites [1] Balkwill, 2001, Inflammation and cancer: Back to virchow?, Lancet source
- cites [2] Wu, 2009, Inflammation: A driving force speeds cancer metastasis, Cell Cycle source
The “Cancer and chronic inflammation” section links chronic inflammation to cancer development and describes its role in tumor growth and metastasis. The paper supports the claim for cancer, including several cancer types, but does not establish the broader claim about numerous diseases. (LLM, conf=0.86)
Experimental — accuracy not yet measured - cites [3] Dinarello, 2010, Anti-inflammatory agents: Present and future, Cell source
- cites [4] Kong, 2022, Inflammation and atherosclerosis: Signaling pathways and therapeutic intervention, Signal Transduct. Target. Ther. source
The Introduction identifies atherosclerosis as chronic vascular inflammation and describes inflammatory processes that promote plaque progression. The paper supports the claim for atherosclerosis, but the broader assertion about the pathogenesis and progression of numerous diseases is not established by these passages. (LLM, conf=0.86)
Experimental — accuracy not yet measured - cites [5] Rohm, 2022, Inflammation in obesity, diabetes, and related disorders, Immunity source
Probably not a substantial claim: may not pass S3 (load-bearing).
PremisecitationPicroside II is biosynthesized via the degradation of ferulic acid to vanillic acid.
“Varun Kumar et al. [25] reported that picroside II is biosynthesized via the degradation of ferulic acid to vanillic acid.”
Quote in the paperNot a substantial claim1 of 1 sources checked- cites [25] Kumar, V., Bansal, A., and Chauhan, R.S. (2017). Modular design of picroside-II biosynthesis deciphered through NGS transcriptomes and metabolic intermediates analysis in naturally variant chemotypes of a medicinal herb, Picrorhiza kurroa. Front. Plant Sci., 8. source
May combine two claims.
PremisecitationExtracellular HMGB1 is a proinflammatory mediator that binds RAGE, TLR2, and TLR4, activates NF-κB, and increases inflammatory factor expression and release.
“Many research studies have shown that extracellular HMGB1 is an effective proinflammatory medium [49,50].”
- Also stated in: § 3.1. Core Anti-Inflammatory Mechanism of Picroside II · plain
“This binding further activates NF-κB, ultimately leading to increased expression and release of multiple inflammatory factors [52].”
Quote in the paperSubstantial claim3 of 3 sources checked- cites [49] Tsung, 2014, High-mobility group box-1 in sterile inflammation, J. Intern. Med. source
- cites [50] Magna, 2014, The role of hmgb1 in the pathogenesis of inflammatory and autoimmune diseases, Mol. Med. source
- cites [52] Wang, 2020, Hmgb1 participates in LPS-induced acute lung injury by activating the aim2 inflammasome in macrophages and inducing polarization of m1 macrophages via TLR2, TLR4, and RAGE/NF-κB signaling pathways, Int. J. Mol. Med. source
- Also stated in: § 3.1. Core Anti-Inflammatory Mechanism of Picroside II · plain
May combine two claims.
PremisecitationPicroside II effectively inhibits cancer cell metastasis and angiogenesis both in vitro and in vivo.
“Picroside II effectively inhibits cancer cell metastasis and angiogenesis both in vitro and in vivo, representing a promising candidate for cancer therapy [110].”
Quote in the paperNot a substantial claim1 of 1 sources checked- cites [110] Lou, 2019, Picroside II, an iridoid glycoside from Picrorhiza kurroa, suppresses tumor migration, invasion, and angiogenesis in vitro and in vivo, Biomed. Pharmacother. source
Classified as probably not a substantial claim.
PremisecitationExcessive or dysregulated inflammation is a major driver of tissue damage and the pathogenesis of numerous diseases, including stroke, Parkinson's disease, atherosclerosis, and cancer.
“Excessive or dysregulated inflammation is a major driver of tissue damage and the pathogenesis of numerous diseases, including stroke, Parkinson’s disease, atherosclerosis, and cancer [9,30,31,32,33].”
Quote in the paperSubstantial claim4 of 5 sources checked- cites [9] Tasneem, 2019, Molecular pharmacology of inflammation: Medicinal plants as anti-inflammatory agents, Pharmacol. Res. source
- cites [30] Mantovani, 2008, Cancer-related inflammation, Nature source
The Cancer-related inflammation section (p. 1) says chronic inflammation increases cancer risk, and Tumour-infiltrating leukocytes (p. 4) describes a pathway involving inflammation and tissue damage. These passages support the cancer and tissue-damage portions of the sentence, but the paper does not establish the claimed role in stroke, Parkinson’s disease, or atherosclerosis. (LLM, conf=0.87)
Experimental — accuracy not yet measured - cites [31] Sagris, M., Theofilis, P., Antonopoulos, A.S., Oikonomou, E., Paschaliori, C., Galiatsatos, N., Tsioufis, K., and Tousoulis, D. (2021). Inflammation in coronary microvascular dysfunction. Int. J. Mol. Sci., 22. source
The Introduction and section 3.1 link inflammation to coronary atherosclerosis and coronary microvascular dysfunction. The copy does not establish the broader claim about tissue damage or the pathogenesis of stroke, Parkinson’s disease, and cancer; searches for those diseases found no supporting passage. No page numbers were available in the copy. (LLM, conf=0.86)
Experimental — accuracy not yet measured - cites [32] Simats, 2022, Systemic inflammation after stroke: Implications for post-stroke comorbidities, EMBO Mol. Med. source
The Acute systemic inflammatory response section says inflammatory cytokines contribute to blood–brain barrier breakdown and are associated with larger infarcts after stroke. The Atherosclerosis section describes inflammatory mechanisms throughout plaque formation. Our copy does not address Parkinson’s disease or cancer in this connection, so it supports only part of the disease list attributed to this source (no page numbers are available). (LLM, conf=0.87)
Experimental — accuracy not yet measured - cites [33] Leńska-Mieciek, M., Madetko-Alster, N., Alster, P., Królicki, L., Fiszer, U., and Koziorowski, D. (2023). Inflammation in multiple system atrophy. Front. Immunol., 14. source
The sections “Immune response in MSA brain parenchyma” and “Conclusion and remarks” (page numbers unavailable) link inflammation to cell injury and propose a role in neurodegenerative disease. The paper says it is uncertain whether inflammation is a primary driver of MSA, and the passages do not support extending that claim to stroke, atherosclerosis, or cancer. (LLM, conf=0.87)
Experimental — accuracy not yet measured
May combine two claims.
PremisecitationPicroside II exerts antioxidant effects by scavenging free radicals in vivo and alleviating oxidative stress-mediated tissue damage.
“Picroside II exerts antioxidant effects by scavenging free radicals in vivo and alleviating oxidative stress-mediated tissue damage [46,77,78,79,80].”
Quote in the paperSubstantial claim3 of 5 sources checked- cites [46] Piao, 2020, Picroside II improves severe acute pancreatitis-induced intestinal barrier injury by inactivating oxidative and inflammatory TLR4-dependent PI3K/AKT/NF-κB signaling and improving gut microbiota, Oxid. Med. Cell. Longev. source
Results §3.3 reports improved antioxidant markers in picroside II-treated rats with severe acute pancreatitis, and Results §3.2 reports less intestinal barrier injury. The paper does not show that picroside II directly scavenges free radicals in vivo, so it does not support that proposed mechanism. (LLM, conf=0.86)
Experimental — accuracy not yet measured - cites [77] Li, 2019, Picroside II attenuates ischemia/reperfusion testicular injury by alleviating oxidative stress and apoptosis through reducing nitric oxide synthesis, Acta Cir. Bras. source
The Conclusion and Discussion report that Picroside II alleviated oxidative stress and testicular ischemia/reperfusion injury in rats. The Discussion identifies superoxide dismutase—not Picroside II—as a free-radical scavenger; the paper does not establish that Picroside II itself scavenges free radicals in vivo. (LLM, conf=0.86)
Experimental — accuracy not yet measured - cites [78] Cao, 2007, Synergistic protective effect of picroside II and NGF on PC12 cells against oxidative stress induced by H2O2, Pharmacol. Rep.
Not checked in the free run.
- cites [79] Li, 2007, The neuroprotective effect of picroside II from hu-huang-lian against oxidative stress, Am. J. Chin. Med. source
- cites [80] Xu, 2024, The paradox of picroside II: As a natural antioxidant, but may instead futher aggravate liver injury by exacerbating mitochondrial oxidative stress, Toxicol. Res. source
The Discussion (page unavailable) says picroside II can attenuate drug-induced liver injury by reducing oxidative stress, and the Abstract says its protective effect is possible when given before injury. Neither passage establishes that it scavenges free radicals in vivo; the paper also reports that administration after injury may worsen liver damage. (LLM, conf=0.86)
Experimental — accuracy not yet measured
May combine two claims.
InterpretationcitationPicroside II protects against allergic asthma by suppressing GATA3 expression and Th2 cytokine bias.
“Picroside II markedly decreased GATA3 and Th2 cytokine expression in differentiating Th2 cells, thereby protecting against allergic asthma by suppressing GATA3 expression and Th2 cytokine bias [68].”
Quote in the paperSubstantial claim1 of 1 sources checked- cites [68] Choi, J., Choi, B.K., Kim, J.S., Lee, J.W., Park, H.A., Ryu, H.W., Lee, S.U., Hwang, K.W., Yun, W.K., and Kim, H.C. (2016). Picroside II attenuates airway inflammation by downregulating the transcription factor GATA3 and Th2-related cytokines in a mouse model of HDM-induced allergic asthma. PLoS ONE, 11. source
The quote only partly states this claim.
PremisecitationPicroside II inhibits NF-κB activation in multiple inflammatory disease models, including endothelial injury and sepsis.
“Wang et al. [41] demonstrated that picroside II can inhibit NF-κB activation in hyperhomocysteinemia (HHcy)-induced endothelial injury.”
- Also stated in: § 3.1. Core Anti-Inflammatory Mechanism of Picroside II · plain
“Huang et al. [43] reported that picroside II inhibited NF-κB and NLRP3 activation in cecal ligation and puncture (CLP)-induced sepsis mice.”
Quote in the paperSubstantial claim1 of 2 sources checked- cites [41] Wang, 2019, Picroside II attenuates hyperhomocysteinemia-induced endothelial injury by reducing inflammation, oxidative stress and cell apoptosis, J. Cell Mol. Med. source
- cites [43] Huang, 2016, Picroside II protects against sepsis via suppressing inflammation in mice, Am. J. Transl. Res.
Not checked in the free run.
- Also stated in: § 3.1. Core Anti-Inflammatory Mechanism of Picroside II · plain
May combine two claims.
PremisecitationPicroside II was nearly undetectable in rat urine after oral dosing, suggesting near-complete metabolic clearance.
“Notably, picroside II was nearly undetectable in rat urine after oral dosing, suggesting near-complete metabolic clearance [23].”
Quote in the paperNot a substantial claim0 of 1 sources checked- cites [23] Zahiruddin, 2017, Pharmacokinetics and comparative metabolic profiling of iridoid enriched fraction of Picrorhiza kurroa—An ayurvedic herb, J. Ethnopharmacol. source
May combine two claims. The quote only partly states this claim.
PremisecitationPicroside II provides neuroprotection in brain-injured mice and reduces neuropathic pain and spinal inflammatory cytokine levels.
“Wang et al. [42] reported that 20 mg/kg picroside II may restore neural function and provide neuroprotection in brain-injured mice.”
- Also stated in: § 3.2. Pharmacological Study on Anti-Inflammatory Effects of Picroside II · plain
“Picroside II significantly reversed mechanical allodynia and thermal hyperalgesia induced by chronic constrictive injury and reduced mRNA and protein levels of IL-1β, IL-6, and TNF-α in the spinal cord [48].”
Quote in the paperSubstantial claim0 of 2 sources checked- cites [42] Wang, 2016, Neuroprotective effect of picroside II in brain injury in mice, Am. J. Transl. Res.
- cites [48] Nong, 2018, Picroside II attenuates cci-induced neuropathic pain in rats by inhibiting spinal reactive astrocyte-mediated neuroinflammation through the NF-κB pathway, Neurochem. Res. source
- Also stated in: § 3.2. Pharmacological Study on Anti-Inflammatory Effects of Picroside II · plain
May combine two claims.
PremisecitationPicroside II improves renal microcirculation perfusion impaired by ischemia-reperfusion-induced acute kidney injury and attenuates inflammation during acute kidney injury.
“Their results demonstrated that picroside II could improve renal microcirculation perfusion impaired by IRI-AKI and attenuate inflammation during AKI [101].”
Quote in the paperSubstantial claim0 of 1 sources checked- cites [101] Ren, 2024, The therapeutic effect of picroside II in renal ischemia-reperfusion induced acute kidney injury: An experimental study, Eur. J. Pharmacol. source
Probably not a substantial claim: may not pass S3 (load-bearing).
Interpretationnone givenExisting research has mainly focused on picroside II's anti-inflammatory, antioxidant, and anti-apoptotic properties.
“In summary, picroside II acts as a multi-system protective agent, and existing research has mainly focused on its anti-inflammatory, antioxidant, and anti-apoptotic properties.”
Quote in the paperNot a substantial claimMay combine two claims.
PremisecitationPicroside II exhibits the highest hepatic uptake and can cross the blood-brain barrier following intravenous administration in rats.
“Consistent with its clinically reported hepatoprotective or neuroprotective effects, picroside II exhibits the highest hepatic uptake and can cross the blood–brain barrier (BBB) following intravenous administration in rats [13].”
Quote in the paperNot a substantial claim0 of 1 sources checked- cites [13] Zhu, 2015, A pre-clinical pharmacokinetic study in rats of three naturally occurring iridoid glycosides, picroside-I, II, and III, using a validated simultaneous HPLC-MS/MS assay, J. Chromatogr. B Anal. Technol. Biomed. Life Sci. source
May combine two claims.
PremisecitationFollowing intravenous administration, picroside II is rapidly excreted and widely distributed in rats.
“Following intravenous administration, it is rapidly excreted and widely distributed in rats [13,21].”
Quote in the paperNot a substantial claim0 of 2 sources checked- cites [13] Zhu, 2015, A pre-clinical pharmacokinetic study in rats of three naturally occurring iridoid glycosides, picroside-I, II, and III, using a validated simultaneous HPLC-MS/MS assay, J. Chromatogr. B Anal. Technol. Biomed. Life Sci. source
- cites [21] Upadhyay, 2016, In vitro—In vivo metabolism and pharmacokinetics of picroside I and II using lc-esi-ms method, Chem. Biol. Interact. source
May combine two claims.
PremisecitationPicroside II reduces inflammation and enhances immune function in septic mice by inhibiting activation of the NLRP3 inflammasome and NF-κB pathway.
“Picroside II reduces inflammation and enhances immune function in septic mice by inhibiting the activation of the NLRP3 inflammasome and NF-κB pathway [43].”
Quote in the paperSubstantial claim0 of 1 sources checked- cites [43] Huang, 2016, Picroside II protects against sepsis via suppressing inflammation in mice, Am. J. Transl. Res.
Not checked in the free run.
May combine two claims.
InterpretationreasoningPicroside II exerts a significant protective effect on cerebral ischemia, particularly through its anti-inflammatory properties.
“As a natural product, picroside IIexerts a significant protective effect on cerebral ischemia, particularly through its anti-inflammatory properties s.”
Quote in the paperSubstantial claimMay combine two claims.
PremisecitationPicroside II possesses significant anti-hepatitis C virus (HCV) entry and anti-infection activities.
“A study of 14 iridoid analogues further revealed that picroside II possesses significant anti-hepatitis C virus (HCV) entry and anti-infection activities [111].”
Quote in the paperNot a substantial claim0 of 1 sources checked- cites [111] Zhang, 2009, Lamiridosins, hepatitis c virus entry inhibitors from lamium album, J. Nat. Prod. source
May combine two claims.
PremisecitationPicroside II is highly hydrophilic, poorly absorbed in the gastrointestinal tract, susceptible to hydrolysis therein, and mainly excreted via bile and urine.
“Studies have shown that picroside II is highly hydrophilic, with poor absorption in the gastrointestinal tract and susceptibility to hydrolysis therein; it is mainly excreted via bile and urine [22].”
Quote in the paperNot a substantial claim0 of 1 sources checked- cites [22] Upadhyay, 2013, Comparative pharmacokinetic profiles of picrosides I and II from kutkin, Picrorhiza kurroa extract and its formulation in rats, Fitoterapia source
May combine two claims.
PremisecitationIn a 6 h acute toxicity test in mice, oral administration of picroside II did not induce obvious toxic reactions, abnormal behavioral changes, organic damage, or animal death, with no significant abnormalities detected in hematological and serum biochemical indices.
“In a 6 h acute toxicity test in mice, oral administration of picroside II did not induce obvious toxic reactions, abnormal behavioral changes, organic damage, or animal death, with no significant abnormalities detected in hematological and serum biochemical indices [22,23].”
Quote in the paperSubstantial claim0 of 2 sources checked- cites [22] Upadhyay, 2013, Comparative pharmacokinetic profiles of picrosides I and II from kutkin, Picrorhiza kurroa extract and its formulation in rats, Fitoterapia source
- cites [23] Zahiruddin, 2017, Pharmacokinetics and comparative metabolic profiling of iridoid enriched fraction of Picrorhiza kurroa—An ayurvedic herb, J. Ethnopharmacol. source
May combine two claims.
PremisecitationThe metabolism of picroside II occurs primarily in the liver and is mediated by the CYP450 enzyme system.
“In summary, the metabolism of picroside II occurs primarily in the liver and is mediated by the CYP450 enzyme system [28].”
Quote in the paperNot a substantial claim0 of 1 sources checked- cites [28] Zhou, 2023, Evaluation potential effects of picroside II on cytochrome p450 enzymes in vitro and in vivo, J. Ethnopharmacol. source
May combine two claims.
InterpretationcitationPicroside II exhibits protective effects against severe acute pancreatitis, acute limb ischemia-reperfusion injury, cancer, and learning and memory dysfunction.
“Picroside II exhibits protective effects against severe acute pancreatitis, acute limb I/R injury, cancer, learning, and memory dysfunction.”
Quote in the paperSubstantial claimMay combine two claims.
PremisecitationPicroside II reduces expression of classic pro-inflammatory cytokines, including IL-1β, IL-6, and TNF-α, in brain-injured mice and in neuropathic pain and astrocyte models.
“Similarly, picroside II reduced the expression of these classic pro-inflammatory cytokines in brain-injured mice [42].”
- Also stated in: § 3.1. Core Anti-Inflammatory Mechanism of Picroside II · plain
“Furthermore, picroside II downregulated mRNA and protein levels of IL-1β, IL-6, and TNF-α in both carbon tetrachloride-induced neuropathic pain mouse models and LPS-stimulated astrocytes [48].”
Quote in the paperSubstantial claim0 of 2 sources checked- cites [42] Wang, 2016, Neuroprotective effect of picroside II in brain injury in mice, Am. J. Transl. Res.
- cites [48] Nong, 2018, Picroside II attenuates cci-induced neuropathic pain in rats by inhibiting spinal reactive astrocyte-mediated neuroinflammation through the NF-κB pathway, Neurochem. Res. source
- Also stated in: § 3.1. Core Anti-Inflammatory Mechanism of Picroside II · plain
May combine two claims.
PremisecitationIn acute lung injury models, picroside II significantly reduces TNF-α, IL-1β, and IL-6 levels both in vitro and in mouse tissues while inhibiting activation of the NF-κB p65 signaling pathway.
“In acute lung injury models, picroside II significantly reduced TNF-α, IL-1β, and IL-6 levels both in vitro and in mouse tissues, while inhibiting activation of the NF-κB p65 signaling pathway [44].”
Quote in the paperSubstantial claim0 of 1 sources checked- cites [44] Shen, 2017, Picroside II protects rat lung and A549 cell against LPS-induced inflammation by the NF-κB pathway, Inflammation source
Probably not a substantial claim: may not pass S2 (checkable). May combine two claims.
InterpretationreasoningPicroside II is a promising anti-inflammatory agent with value for future research and clinical applications.
“Such pharmacological actions render picroside II a promising anti-inflammatory agent, which holds great value for future research and clinical applications.”
Quote in the paperNot a substantial claimMay combine two claims.
PremisecitationIn a 6-month study in beagle dogs, picroside II at 10-30 mg/kg body weight daily oral doses showed no cumulative toxicity and no abnormal physiological or biochemical changes.
“A 6-month study in beagle dogs further confirmed no cumulative toxicity of picroside II at 10–30 mg/kg body weight (bw) daily oral doses, with no abnormal physiological or biochemical changes detected [24].”
Quote in the paperSubstantial claim0 of 1 sources checked- cites [24] Yang, 2005, Determination of picroside II in dog plasma by HPLC and its application in a pharmacokinetics study, Biomed. Chromatogr. source
May combine two claims.
InterpretationreasoningMost evidence on picroside II is based on in vitro cell experiments and rodent models, with limited validation in large animals or well-designed clinical trials, leaving translational uncertainty in humans.
“First, most evidence is based on in vitro cell experiments and rodent models, with limited validation in large animals or well-designed clinical trials, leaving translational uncertainty in humans.”
Quote in the paperSubstantial claim
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
Each contradiction between two passages listed here was confirmed by an independent check.
HMGB1 is assigned conflicting locations in other tissues
MinorThe sentence says HMGB1 is mainly cytoplasmic outside the liver and brain, then says it is primarily nuclear in most other tissues.
“Except for liver and brain tissue, HMGB1 is mainly present in the cytoplasm”
“in most other tissues, it is primarily located in the nucleus”
The neuropathic-pain model attributed to reference 48 changes
MinorThe paper attributes a carbon tetrachloride-induced mouse model to reference 48, but elsewhere describes the neuropathic-pain work cited to that reference as a chronic constriction injury model in rats.
“in both carbon tetrachloride-induced neuropathic pain mouse models and LPS-stimulated astrocytes [48]”
“in rats with neuropathic pain [48].”
Dog clearance is both above and below human clearance
MinorThe stated fold changes put hepatic clearance in dogs 2.3 times higher than in humans, but the stated ranking places humans above dogs.
“the intrinsic clearance rates of hepatic glucosylation of picroside II in rats, mice, and dogs were 10.6-fold, 6.0-fold, and 2.3-fold higher than those in humans, respectively.”
“the sequence of glucosylation activity of picroside II liver microsomes was rats > mice > humans > dogs”
Cites
Mantovani, A., Allavena, P., Sica, A., & Balkwill, F. (2008) · Nature · doi:10.1038/nature07205 · Cited by 11,399 · cited 1× · see citing works
“Excessive or dysregulated inflammation is a major driver of tissue damage and the pathogenesis of numerous diseases, including stroke, Parkinson’s disease, atherosclerosis, and cancer [9,30–33].”
Inflammation and cancer: back to Virchow?
Balkwill, F., & Mantovani, A. (2001) · The Lancet · doi:10.1016/s0140-6736(00)04046-0 · Cited by 7,746 · cited 1× · see citing works
“Inflammation acts as a pivotal pathogenic factor and is widely implicated in the occurrence and development of various chronic and common diseases, including malignant tumors, atherosclerosis, and diabetes [1–5].”
Cytokines, Inflammation, and Pain
Zhang, J., & An, J. (2007) · International Anesthesiology Clinics · doi:10.1097/aia.0b013e318034194e · Cited by 2,958 · cited 3× · see citing works
“Cytokines are small peptides or glycoproteins synthesized and secreted by various tissue cells, primarily immune cells [66].”
The NF- B Family of Transcription Factors and Its RegulationPreprint
Oeckinghaus, A., & Ghosh, S. (2009) · Cold Spring Harbor Perspectives in Biology · doi:10.1101/cshperspect.a000034 · Cited by 2,850 · see citing works
Multiple nuclear factors interact with the immunoglobulin enhancer sequences
Sen, R., & Baltimore, D. (1986) · Cell · doi:10.1016/0092-8674(86)90346-6 · Cited by 2,754 · cited 1× · see citing works
“The nuclear factor kappa-B (NF-κ B) protein was first observed by David Baltimore [35].”
Oxidative Stress and Inflammation: What Polyphenols Can Do for Us?
Hussain, T., Tan, B., Yin, Y., Blachier, F., Tossou, M. C. B., & Rahu, N. (2016) · Oxidative Medicine and Cellular Longevity · doi:10.1155/2016/7432797 · Cited by 2,088 · cited 1× · see citing works
“Oxidative stress can induce inflammation [72,73].”
Inflammation in obesity, diabetes, and related disorders
Rohm, T. V., Meier, D. T., Olefsky, J. M., & Donath, M. Y. (2022) · Immunity · doi:10.1016/j.immuni.2021.12.013 · Cited by 2,066 · cited 1× · see citing works
“Inflammation acts as a pivotal pathogenic factor and is widely implicated in the occurrence and development of various chronic and common diseases, including malignant tumors, atherosclerosis, and diabetes [1–5].”
Dinarello, C. A. (2000) · CHEST Journal · doi:10.1378/chest.118.2.503 · Cited by 2,047 · cited 2× · see citing works
“The principal anti-inflammatory cytokines include interleukin-1 receptor antagonists, IL-4, IL-10, IL-11, and IL-13 [66,67].”
30 Years of NF-κB: A Blossoming of Relevance to Human Pathobiology
Zhang, Q., Lenardo, M. J., & Baltimore, D. (2017) · Cell · doi:10.1016/j.cell.2016.12.012 · Cited by 1,979 · cited 2× · see citing works
“…NF-κ B then translocates into the nucleus, binds to specific DNA sequences in gene promoters, promotes the transcription of downstream target genes and protein synthesis, and participates in various pathophysiological processes including infection, inflammation, and immune responses [38,39].”
Inflammation 2010: New Adventures of an Old Flame
Medzhitov, R. M. (2010) · Cell · doi:10.1016/j.cell.2010.03.006 · Cited by 1,854 · cited 1× · see citing works
“Failure to modulate proinflammatory stimuli can lead to persistent chronic inflammation, which exacerbates disease progression [9,34].”
Mechanisms and functions of p38 MAPK signalling
Cuadrado, A., & Nebreda, Á. R. (2010) · Biochemical Journal · doi:10.1042/bj20100323 · Cited by 1,679 · cited 2× · see citing works
“Multiple stimuli, including growth factors, cytokines, radiation, and osmotic stress, have been shown to activate MAPK signaling pathways [55].”
Epidemiology of cardiovascular disease in China: current features and implications
Zhao, D. H., Liu, J., Wang, M., Zhang, X., & Zhou, M. (2018) · Nature Reviews Cardiology · doi:10.1038/s41569-018-0119-4 · Cited by 1,407 · cited 1× · see citing works
“The cardiovascular system, composed of the heart and blood vessels, is a common and critical system affected by diseases that seriously threaten human health [96].”
TGF-β and the TGF-β family: context-dependent roles in cell and tissue physiology
Morikawa, M., Derynck, R., & Miyazono, K. (2016) · Cold Spring Harbor Perspectives in Biology · doi:10.1101/cshperspect.a021873 · Cited by 1,321 · cited 1× · see citing works
“Smads are ubiquitously expressed in various cell types, among which Smad 2 and Smad 4 serve as canonical mediators of the TGF-β signaling response [70].”
Banerjee, S., Biehl, A., Gadina, M., Hasni, S., & Schwartz, D. M. (2017) · Drugs · doi:10.1007/s40265-017-0701-9 · Cited by 1,206 · see citing works
Inflammation and atherosclerosis: signaling pathways and therapeutic intervention
Kong, P., Cui, Z.-Y., Huang, X.-F., Zhang, D.-D., Guo, R.-J., & Han, M. (2022) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-022-00955-7 · Cited by 1,183 · see citing works
Anti-inflammatory Agents: Present and Future
Dinarello, C. A. (2010) · Cell · doi:10.1016/j.cell.2010.02.043 · Cited by 1,095 · cited 2× · see citing works
“Pro-inflammatory cytokines are mainly produced by activated macrophages and participate in upregulating inflammatory responses; key examples include IL-1 β , IL-6, and TNF-α [3].”
A Comprehensive Review on MAPK: A Promising Therapeutic Target in Cancer
Braicu, C., Buse, M., Busuioc, C. I., Drulă, R., Gulei, D., Ráduly, L., Alexandru Vasile, R. U. S. U., Irimie, A., Atanasov, A. G., Slaby, O., et al. (2019) · Cancers · doi:10.3390/cancers11101618 · Cited by 940 · cited 1× · see citing works
“Once activated, MAPK promotes inflammatory responses in mammalian cells, such as enhanced secretion of proinflammatory cytokines [55,56].”
Zhang, Q., Liu, J., Duan, H., Li, R., Peng, W., & Wu, C. (2021) · Journal of Advanced Research · doi:10.1016/j.jare.2021.06.023 · Cited by 841 · see citing works
Transforming growth factor-β in T-cell biology
Gorelik, L., & Flavell, R. A. (2002) · Nature Reviews Immunology · doi:10.1038/nri704 · Cited by 792 · see citing works
Regulation of RAF protein kinases in ERK signalling
Lavoie, H., & Therrien, M. (2015) · Nature Reviews Molecular Cell Biology · doi:10.1038/nrm3979 · Cited by 695 · cited 1× · see citing works
“MAPK comprises four subfamilies: extracellular regulated protein kinase (ERK), p38 kinases (p38), c-Jun N-terminal kinases (JNK), and ERK5 [53,54].”
Zhang, Z., Zhao, L. Q., Zhou, X., Meng, X., & Zhou, X. (2023) · Frontiers in Immunology · doi:10.3389/fimmu.2022.1098725 · Cited by 387 · cited 1× · see citing works
“Oxidative stress can induce inflammation [72,73].”
Molecular pharmacology of inflammation: Medicinal plants as anti-inflammatory agents
Tasneem, S., Liu, B., Li, B., Choudhary, M. I., & Wang, W. (2019) · Pharmacological Research · doi:10.1016/j.phrs.2018.11.001 · Cited by 358 · cited 3× · see citing works
“Excessive or dysregulated inflammation is a major driver of tissue damage and the pathogenesis of numerous diseases, including stroke, Parkinson’s disease, atherosclerosis, and cancer [9,30–33].”
The Role of HMGB1 in the Pathogenesis of Inflammatory and Autoimmune Diseases
Magna, M., & Pisetsky, D. S. (2014) · Molecular Medicine · doi:10.2119/molmed.2013.00164 · Cited by 358 · cited 1× · see citing works
“Many research studies have shown that extracellular HMGB1 is an effective proinflammatory medium [49,50].”
What has traditional Chinese medicine delivered for modern medicine?
Wang, J., Wong, Y., & Liao, F. (2018) · Expert Reviews in Molecular Medicine · doi:10.1017/erm.2018.3 · Cited by 327 · see citing works
Inflammation: A driving force speeds cancer metastasis
Wu, Y., & Zhou, B. P. (2009) · Cell Cycle · doi:10.4161/cc.8.20.9699 · Cited by 327 · see citing works
MEK kinases are regulated by EGF and selectively interact with Rac/Cdc42
Fanger, G. R., Johnson, N. L., & Johnson, G. L. (1997) · The EMBO Journal · doi:10.1093/emboj/16.16.4961 · Cited by 297 · cited 1× · see citing works
“MAPK comprises four subfamilies: extracellular regulated protein kinase (ERK), p38 kinases (p38), c-Jun N-terminal kinases (JNK), and ERK5 [53,54].”
Systemic inflammation after stroke: implications for post‐stroke comorbidities
Simats, A., & Liesz, A. (2022) · EMBO Molecular Medicine · doi:10.15252/emmm.202216269 · Cited by 276 · see citing works
High‐mobility group box‐1 in sterile inflammation
Tsung, A., Tohme, S., & Billiar, T. R. (2014) · Journal of Internal Medicine · doi:10.1111/joim.12276 · Cited by 187 · cited 2× · see citing works
“Except for liver and brain tissue, HMGB1 is mainly present in the cytoplasm; in most other tissues, it is primarily located in the nucleus [49–51].”
Shi, X., Zhou, H., Wei, J., Mo, W., Li, Q., & Lv, X. (2022) · Redox Biology · doi:10.1016/j.redox.2022.102553 · Cited by 160 · see citing works
Shimoda, K., Feng, J., Murakami, H., Nagata, S., Watling, D., Rogers, N. C., Stark, G. R., Kerr, I. M., & Ihle, J. N. (1997) · Blood · doi:10.1182/blood.v90.2.597 · Cited by 152 · cited 1× · see citing works
“JAK1 is a non-redundant core kinase responsible for receptor phosphorylation and dominant in the activation of STAT1/3/5 [62].”
Williams, L. M., & Gilmore, T. D. (2020) · Molecular and Cellular Biology · doi:10.1128/mcb.00104-20 · Cited by 128 · cited 1× · see citing works
“NF-κ B is found in almost all animal cells and plays a crucial role in cellular inflammatory and immune response [37].”
Inflammation in Coronary Microvascular Dysfunction
Sagris, M., Theofilis, P., Antonopoulos, A. S., Oikonomou, E., Paschaliori, C., Galiatsatos, N., Tsioufis, K., & Tousoulis, D. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms222413471 · Cited by 115 · see citing works
Matrine Exerts Pharmacological Effects Through Multiple Signaling Pathways: A Comprehensive Review
Lin, Y., He, F., Wu, L., Xu, Y., & Du, Q. (2022) · Drug Design Development and Therapy · doi:10.2147/dddt.s349678 · Cited by 103 · cited 1× · see citing works
“…NF-κ B then translocates into the nucleus, binds to specific DNA sequences in gene promoters, promotes the transcription of downstream target genes and protein synthesis, and participates in various pathophysiological processes including infection, inflammation, and immune responses [38,39].”
Wang, J., Li, R., Peng, Z., Hu, B., Rao, X., & Li, J. (2020) · International Journal of Molecular Medicine · doi:10.3892/ijmm.2020.4530 · Cited by 98 · see citing works
Zhou, J., Peng, Z., & Wang, J. (2021) · Inflammation · doi:10.1007/s10753-021-01435-w · Cited by 97 · cited 1× · see citing works
“During inflammation, immune cells including neutrophils and macrophages accumulate at inflammatory sites and release excessive reactive oxygen species along with inflammatory mediators, forming a vicious cycle [74–76].”
Gu, T., Zhang, Z., Liu, J., Chen, L., Tian, Y., Xu, W., Zeng, T., Wu, W., & Lu, L. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms241713516 · Cited by 82 · cited 2× · see citing works
“During inflammation, immune cells including neutrophils and macrophages accumulate at inflammatory sites and release excessive reactive oxygen species along with inflammatory mediators, forming a vicious cycle [74–76].”
Weinges, K., Kloss, P., & Henkels, W. (1972) · Justus Liebigs Annalen der Chemie · doi:10.1002/jlac.19727590113 · Cited by 80 · cited 1× · see citing works
“Picroside II is an iridoid glycoside formed via an ester linkage between vanillic acid (4-hydroxy-3-methoxybenzoic acid) and catalpol, an iridoid aglycone [14,20].”
Wang, J., Li, R., Peng, Z., Hu, B., Rao, X., & Li, J. (2019) · International Journal of Molecular Medicine · doi:10.3892/ijmm.2019.4402 · Cited by 78 · see citing works
Natural or Plant Products for the Treatment of Neurological Disorders: Current Knowledge
Parvez, M. K. (2017) · Current Drug Metabolism · doi:10.2174/1389200218666170710190249 · Cited by 75 · cited 1× · see citing works
“Natural products with antioxidant and anti-inflammatory properties play an important role in neuronal protection [82].”
Anti-inflammation effects of picroside 2 in cerebral ischemic injury rats
Guo, Y., Xu, X., Li, Q., Li, Z., & Du, F. (2010) · Behavioral and Brain Functions · doi:10.1186/1744-9081-6-43 · Cited by 73 · cited 1× · see citing works
“Additionally, picroside II can downregulate the expression of TLR4, NF-κ B, and TNF-α ; inhibit apoptosis and inflammation in rats with CIRI; and enhance neurobehavioral function [17,87].”
Self-citation“Picrosides” from Picrorhiza kurroa as potential anti-carcinogenic agents
Soni, D., & Grover, A. (2018) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2018.11.048 · Cited by 69 · cited 1× · see citing works
“It is mainly distributed in India and regions of Sichuan, Yunnan, Tibet, and the Himalayas in China [10,11].”
Herb–Drug Interactions of Commonly Used Chinese Medicinal Herbs
Singh, A., & Zhao, K. (2017) · International review of neurobiology · doi:10.1016/bs.irn.2017.02.010 · Cited by 67 · cited 1× · see citing works
“Herbal compounds may alter drug absorption, distribution, and metabolism by inducing or inhibiting metabolic enzymes and transporters, which may reduce therapeutic efficacy and even result in treatment failure [26,27].”
Lamiridosins, Hepatitis C Virus Entry Inhibitors from <i>Lamium album</i>
Zhang, H., Rothwangl, K., Mesecar, A. D., Sabahi, A., Rong, L., & Fong, H. H. S. (2009) · Journal of Natural Products · doi:10.1021/np900549e · Cited by 65 · see citing works
Zahiruddin, S., Khan, W., Nehra, R., Alam, M. J., Mallick, M. N., Parveen, R., & Ahmad, S. (2017) · Journal of Ethnopharmacology · doi:10.1016/j.jep.2016.07.072 · Cited by 61 · cited 2× · see citing works
“In a 6 h acute toxicity test in mice, oral administration of picroside II did not induce obvious toxic reactions, abnormal behavioral changes, organic damage, or animal death, with no significant abnormalities detected in hematological and serum biochemical indices [22,23].”
Inhibitory effect of picroside II on hepatocyte apoptosis
Gao, H., & Zhou, Y. (2005) · Acta Pharmacologica Sinica · doi:10.1111/j.1745-7254.2005.00729.x · Cited by 58 · cited 1× · see citing works
“Picroside II protects hepatocytes from damage and inhibits hepatocyte apoptosis [104].”
Li, T., Xu, L., Zheng, R., Wang, X., Li, L., Ji, H., & Hu, Q. (2019) · Phytomedicine · doi:10.1016/j.phymed.2019.153153 · Cited by 56 · cited 1× · see citing works
“Furthermore, picroside II may regulate the transporters and enzymes involved in bile acid homeostasis by activating the farnesoid X receptor (FXR), thereby protecting against anti-alpha-naphthylisothiocyanate (ANIT)-induced cholestasis [106].”
Piao, X., Liu, B., Sui, X., Li, S., Niu, W., Zhang, Q., Shi, X., Cai, S., & Fan, Y. (2020) · Oxidative Medicine and Cellular Longevity · doi:10.1155/2020/3589497 · Cited by 53 · cited 4× · see citing works
“Picroside II may inhibit NF-κ B expression in rats with severe acute pancreatitis (SAP), thereby reducing the levels of inflammatory cytokines including IL-1 β , IL-6, and tumor necrosis factor-α (TNF-α ) [45,46].”
InfluentialNeuroprotective Properties of Picroside II in a Rat Model of Focal Cerebral Ischemia
Li, Q., Li, Z., Xu, X., Guo, Y., & Du, F. (2010) · International Journal of Molecular Sciences · doi:10.3390/ijms11114580 · Cited by 52 · cited 1× · see citing works
“When 10 mg/kg picroside II was injected into the tail vein of MCAO/R Wistar rats , the treatment group showed significantly reduced Bederson’s scores, infarct size, caspase-3 and PARP expression, and apoptotic rates compared with the control group [92].”
Self-citationAnti-lipid peroxidation and protection of liver mitochondria against injuries by picroside II
Gao, H. (2005) · World Journal of Gastroenterology · doi:10.3748/wjg.v11.i24.3671 · Cited by 50 · cited 1× · see citing works
“Picroside II significantly alleviates hepatocyte injury induced by carbon tetrachloride (CCl 4 ) and modulates hepatic energy metabolism balance [109].”
Kiso, Y., Tohkin, M., & Hikino, H. (1983) · Journal of Natural Products · doi:10.1021/np50030a003 · Cited by 50 · cited 1× · see citing works
“In 1983, Kiso et al. [103] identified remarkable anti-hepatotoxic activity of picroside II in primary cultured hepatocytes induced by galactosamine.”
WANG, L., LIU, X.-H., CHEN, H., CHEN, Z.-Y., WENG, X.-D., QIU, T., & LIU, L. (2015) · Experimental and Therapeutic Medicine · doi:10.3892/etm.2015.2225 · Cited by 46 · cited 2× · see citing works
“Wang et al. [47] confirmed that picroside II also inhibited NF-κ B in a rat model of renal ischemia–reperfusion (I/R) injury.”
Katoch, M., Fazli, I. S., Suri, K. A., et al. (2011) · Journal of Natural Medicines · doi:10.1007/s11418-010-0491-9 · Cited by 46 · see citing works
Inflammation in multiple system atrophy
Leńska-Mieciek, M., Madetko-Alster, N., Alster, P., Królicki, L., Fiszer, U., & Koziorowski, D. (2023) · Frontiers in Immunology · doi:10.3389/fimmu.2023.1214677 · Cited by 45 · cited 1× · see citing works
“Excessive or dysregulated inflammation is a major driver of tissue damage and the pathogenesis of numerous diseases, including stroke, Parkinson’s disease, atherosclerosis, and cancer [9,30–33].”
Upadhyay, D., Dash, R. P., Anandjiwala, S., & Nivsarkar, M. (2013) · Fitoterapia · doi:10.1016/j.fitote.2013.01.004 · Cited by 45 · cited 5× · see citing works
“In a 6 h acute toxicity test in mice, oral administration of picroside II did not induce obvious toxic reactions, abnormal behavioral changes, organic damage, or animal death, with no significant abnormalities detected in hematological and serum biochemical indices [22,23].”
InfluentialWang, X.-H., Zhang, S., Shi, M., et al. (2020) · Technology in Cancer Research & Treatment · doi:10.1177/1533033820948054 · Cited by 44 · cited 1× · see citing works
“Except for liver and brain tissue, HMGB1 is mainly present in the cytoplasm; in most other tissues, it is primarily located in the nucleus [49–51].”
Husain, I., Dale, O. R., Martin, K., et al. (2022) · Journal of Ethnopharmacology · doi:10.1016/j.jep.2022.115822 · Cited by 44 · see citing works
The Neuroprotective Effect of Picroside II from Hu-Huang-Lian against Oxidative Stress
Li, T., Liu, J.-W., Zhang, X.-D., Guo, M.-C., & Ji, G. (2007) · The American Journal of Chinese Medicine · doi:10.1142/s0192415x0700517x · Cited by 41 · cited 2× · see citing works
“In addition, picroside II at 20 and 40 mg/kg/day significantly attenuated AlCl 3 -induced learning and memory dysfunction in mice [79].”
Lou, C., Zhu, Z., Xu, X., Zhu, R., Sheng, Y., & Zhao, H. (2019) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2019.109494 · Cited by 41 · cited 1× · see citing works
“Picroside II effectively inhibits cancer cell metastasis and angiogenesis both in vitro and in vivo, representing a promising candidate for cancer therapy [110].”
Effect of picroside II on apoptosis induced by renal ischemia/reperfusion injury in rats
Wang, L., Liu, X., Chen, H., Chen, Z., Weng, X., Qiu, T., & Liu, L. (2015) · Experimental and Therapeutic Medicine · doi:10.3892/etm.2015.2192 · Cited by 38 · cited 1× · see citing works
“Furthermore, picroside II treatment attenuated tissue injury and suppressed the expression of cleaved caspase-3 triggered by renal I/R injury [102].”
(2007) · PubMed · Cited by 38 · see citing works
Dhami-Shah, H., Vaidya, R., Udipi, S., Raghavan, S., Abhijit, S., Mohan, V., Balasubramanyam, M., & Vaidya, A. (2018) · Clinical and Molecular Hepatology · doi:10.3350/cmh.2017.0039 · Cited by 36 · cited 1× · see citing works
“Pretreatment with picroside II ameliorated lipid accumulation induced by hepatic steatosis [105].”
A novel treatment for psoriatic arthritis: Janus kinase inhibitors
Chen, M., & Dai, S. (2020) · Chinese Medical Journal · doi:10.1097/cm9.0000000000000711 · Cited by 33 · cited 1× · see citing works
“Phosphorylation of STATs can drive the transcription of inflammation-related genes, and dysregulated JAK-STAT signaling may lead to a range of diseases, including skin diseases, cancer, and immune disorders [63,64].”
Piao, X., Liu, B., Guo, L., Meng, F., & Gao, L. (2017) · Oxidative Medicine and Cellular Longevity · doi:10.1155/2017/7085709 · Cited by 32 · cited 2× · see citing works
“Picroside II may inhibit NF-κ B expression in rats with severe acute pancreatitis (SAP), thereby reducing the levels of inflammatory cytokines including IL-1 β , IL-6, and tumor necrosis factor-α (TNF-α ) [45,46].”
Ma, S., Wang, X., Lai, F., & Lou, C. (2020) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2020.110421 · Cited by 32 · cited 3× · see citing works
“In recent years, natural products have emerged as promising sources of novel anti-inflammatory drugs due to their high biological activities and low toxicity [6–9].”
Picroside II Protects Rat Lung and A549 Cell Against LPS-Induced Inflammation by the NF-κB Pathway
Shen, B., Zhao, C., Chen, C., Li, Z., Li, Y., Tian, Y., & Feng, H. (2017) · Inflammation · doi:10.1007/s10753-017-0519-3 · Cited by 31 · cited 2× · see citing works
“In acute lung injury models, picroside II significantly reduced TNF-α , IL-1 β , and IL-6 levels both in vitro and in mouse tissues, while inhibiting activation of the NF-κ B p65 signaling pathway [44].”
Kumar, V., Bansal, A., & Chauhan, R. S. (2017) · Frontiers in Plant Science · doi:10.3389/fpls.2017.00564 · Cited by 31 · cited 1× · see citing works
“Varun Kumar et al. [25] reported that picroside II is biosynthesized via the degradation of ferulic acid to vanillic acid.”
Choi, J., Choi, B. K., Kim, J. S., Lee, J.-W., Park, H. A., Ryu, H. W., Lee, S. U., Hwang, K. W., Yun, W.-K., Kim, H.-C., et al. (2016) · PLOS ONE · doi:10.1371/journal.pone.0167098 · Cited by 30 · cited 2× · see citing works
“ELISA results revealed that picroside II downregulated Th2-related cytokines (IL-4, IL-5, and IL-13) and upregulated the Th1-related cytokine IFN-γ in bronchoalveolar lavage fluid (BALF) [68].”
Picroside II Inhibits the MEK-ERK1/2-COX2 Signal Pathway to Prevent Cerebral Ischemic Injury in Rats
Wang, T., Zhai, L., Zhang, H., Zhao, L., & Guo, Y. (2015) · Journal of Molecular Neuroscience · doi:10.1007/s12031-015-0623-5 · Cited by 28 · cited 1× · see citing works
“Using LPS as an activator of the ERK1/2 pathway and U0126 as an inhibitor, researchers found that picroside II could inhibit the ERK1/2 pathway, reduce the expression of cyclooxygenase 2 (COX2), decrease cerebral infarct volume, and protect neurons in the cortical ischemic area [88–91].”
Self-citationMENG, F.-J., JIAO, S.-M., & YU, B. (2012) · International Journal of Molecular Medicine · doi:10.3892/ijmm.2012.987 · Cited by 28 · cited 1× · see citing works
“This study demonstrated that picroside II inhibits I/R-induced cardiomyocyte apoptosis by activating the phosphatidylinositol-3-kinase/protein kinase B/cAMP-response element binding protein (PI3K/Akt/CREB) pathway and regulating the expression of Bcl-2 and Bax [98].”
Nong, X., & Lan, Y. (2018) · Neurochemical Research · doi:10.1007/s11064-018-2518-7 · Cited by 26 · cited 4× · see citing works
“The analgesic effect of picroside II was associated with the inhibition of spinal reactive astrocyte-mediated neuroinflammation via the NF-κ B pathway in rats with neuropathic pain [48].”
InfluentialLi, J.-Z., Xie, M.-Q., Mo, D., Zhao, X.-F., Yu, S.-Y., Liu, L.-J., Wu, C., & Yang, Y. (2016) · Experimental and Therapeutic Medicine · doi:10.3892/etm.2016.3841 · Cited by 25 · see citing works
Wang, Y., Hong, Y., Zhang, C., Shen, Y., Pan, Y. S., Chen, R. Z., Zhang, Q., & Chen, Y. H. (2019) · Journal of Cellular and Molecular Medicine · doi:10.1111/jcmm.13949 · Cited by 25 · cited 2× · see citing works
“Wang et al. [41] demonstrated that picroside II can inhibit NF-κ B activation in hyperho-mocysteinemia (HHcy)-induced endothelial injury.”
Self-citationPei, H., Su, X., Zhao, L., Li, H., Guo, Y., Zhang, M., & Xin, H. (2012) · International Journal of Molecular Sciences · doi:10.3390/ijms13032551 · Cited by 24 · cited 1× · see citing works
“Pei et al. [85] also found that the optimal dose and time window for picroside II in the treatment of ischemic brain injury was intraperitoneal injection of 20 mg/kg body weight at 1.5 h after ischemia.”
InfluentialSelf-citationZhai, L., Liu, M., Wang, T., Zhang, H., Li, S., & Guo, Y. (2017) · PLoS ONE · doi:10.1371/journal.pone.0174414 · Cited by 24 · cited 2× · see citing works
“It may also decrease the expressions of Rho-associated coiled-coil protein kinase (ROCK), myosin light chain kinase (MLCK), and MMP2, while enhancing the expression of claudin-5, thus protecting the blood–brain barrier [81].”
Self-citationGao, Y., Song, G., Cao, Y., Yan, K., Li, B., Zhu, X.-F., Wang, Y., Xing, Z., Cui, L., Wang, X., et al. (2019) · Evidence-based Complementary and Alternative Medicine · doi:10.1155/2019/1947465 · Cited by 24 · cited 1× · see citing works
“Inflammation plays a central role in the pathogenesis of myocardial I/R injury [97].”
Self-citationZhao, L., Guo, Y., Ji, X., & Zhang, M. (2014) · BMC Neuroscience · doi:10.1186/1471-2202-15-25 · Cited by 23 · cited 1× · see citing works
“On the basis of a therapeutic window and dose-finding rationale, the optimal therapeutic dose and time window for cerebral ischemic injury were determined as intraperitoneal injection of 10–20 mg/kg picroside II at 1.5–2.0 h after ischemia onset [83].”
InfluentialSelf-citationMeng, F., Hou, Z., Li, Y., Yang, Y., & Yu, B. (2012) · Pharmaceutical Biology · doi:10.3109/13880209.2012.664555 · Cited by 23 · cited 1× · see citing works
“…(50–200 µ g/mL) showed increased cell viability in a dose-dependent manner, accompanied by significantly reduced glutathione (GSH) content, decreased superoxide dismutase (SOD) and glutathione peroxidase (GSH-PX) activity, and lower malondialdehyde (MDA) and oxidized glutathione (GSSG) levels [99].”
Surmacki, J. M., & Abramczyk, H. (2023) · Scientific Reports · doi:10.1038/s41598-023-42301-z · Cited by 21 · see citing works
Picroside II protects against sepsis via suppressing inflammation in mice.
(2016) · PubMed Central · Cited by 19 · see citing works
Determination of picroside II in dog plasma by HPLC and its application in a pharmacokinetics study
Yang, F., Yang, S., & Xu, L. (2005) · Biomedical Chromatography · doi:10.1002/bmc.453 · Cited by 18 · cited 2× · see citing works
“A 6-month study in beagle dogs further confirmed no cumulative toxicity of picro-side II at 10–30 mg/kg body weight (bw) daily oral doses, with no abnormal physiological or biochemical changes detected [24].”
LI, J.-Z., YU, S.-Y., MO, D., TANG, X.-N., & SHAO, Q.-R. (2015) · International Journal of Molecular Medicine · doi:10.3892/ijmm.2014.2009 · Cited by 18 · see citing works
Yang, X., Gao, W., Wang, B., Wang, X., Guo, H. B., Yuan, X. H., Kong, L., & Hao, D. (2017) · Journal of Cellular Biochemistry · doi:10.1002/jcb.26105 · Cited by 18 · cited 2× · see citing works
“In addition, Yang et al. [59] demonstrated that picroside II significantly reduced the phosphorylation degradation of p38, ERK, JNK, p65, and I κ B in RANKL-induced bone loss in vitro and LPS-induced inflammation in vivo.”
Zhu, J., Xue, B., Ma, B., Zhang, Q., Liu, M., Liu, L., Yao, D., Qi, H., Wang, Y., Ying, H., et al. (2015) · Journal of Chromatography B · doi:10.1016/j.jchromb.2015.04.036 · Cited by 17 · cited 3× · see citing works
“Picroside II exhibits potent hepatoprotective effects due to its high hepatic uptake [13].”
Self-citationYao, H., Yan, J., Yin, L., & Chen, W. (2022) · Immunopharmacology and Immunotoxicology · doi:10.1080/08923973.2022.2054425 · Cited by 17 · cited 3× · see citing works
“In a recent study, Yao et al. [40] investigated the anti-inflammatory effects of picroside II in a mouse model of dextran sodium sulfate (DSS)-induced ulcerative colitis and in lipopolysaccharide (LPS)-stimulated macrophages.”
InfluentialWang, T., Zhu, L., Liu, H., Yu, G., & Guo, Y. (2019) · The Anatomical Record · doi:10.1002/ar.24214 · Cited by 17 · cited 1× · see citing works
“By establishing an oxygen–glucose deprivation/reperfusion (OGD/R) model using SH-SY5Y cells in vitro, picroside II was shown to improve cell viability, reduce cytotoxicity, and inhibit apoptosis and autophagy in SH-SY5Y cells by suppressing the JNK signaling pathway [95].”
Self-citationLi, T., Zheng, R., Xu, L., Zhou, M., Wang, X., Guo, Q., Ji, H., & Li, L. (2020) · Toxicology and Applied Pharmacology · doi:10.1016/j.taap.2020.115248 · Cited by 17 · cited 1× · see citing works
“It reduces serum biochemical indices, relieves histological damage, and inhibit the phosphorylation of ERK1/2, LKB1, and AMPK in ANIT-induced cholestasis [108].”
In vitro – In vivo metabolism and pharmacokinetics of picroside I and II using LC-ESI-MS method
Upadhyay, D., Anandjiwala, S., Padh, H., & Nivsarkar, M. (2016) · Chemico-Biological Interactions · doi:10.1016/j.cbi.2016.05.031 · Cited by 16 · cited 1× · see citing works
“Following intravenous administration, it is rapidly excreted and widely distributed in rats [13,21].”
Wang, T., Zhai, L., Guo, Y., Pei, H., & Zhang, M. (2015) · Clinical and Experimental Pharmacology and Physiology · doi:10.1111/1440-1681.12445 · Cited by 12 · see citing works
Self-citationWang, T., Zhao, L., Guo, Y., Zhang, M., & Pei, H. (2015) · PLoS ONE · doi:10.1371/journal.pone.0124099 · Cited by 12 · cited 1× · see citing works
“Using LPS as an activator of the ERK1/2 pathway and U0126 as an inhibitor, researchers found that picroside II could inhibit the ERK1/2 pathway, reduce the expression of cyclooxygenase 2 (COX2), decrease cerebral infarct volume, and protect neurons in the cortical ischemic area [88–91].”
Self-citationLee, K., Choi, J., Choi, B. K., Gu, Y.-M., Ryu, H. W., Oh, S.-R., & Lee, H.-J. (2019) · Molecules · doi:10.3390/molecules24102020 · Cited by 11 · cited 3× · see citing works
“Lee et al. [58] evaluated the inhibitory effect of picroside II on MAPK signaling in LPS-stimulated human monocytes as a model of chronic obstructive pulmonary disease (COPD).”
InfluentialPicroside II decreases the development of fibrosis induced by ischemia/reperfusion injury in rats
Wang, L., Liu, X.-H., Chen, H., Chen, Z.-Y., Weng, X.-D., Qiu, T., & Liu, L. (2014) · Renal Failure · doi:10.3109/0886022x.2014.949766 · Cited by 10 · cited 2× · see citing works
“Previous studies have shown that after CIRI in rats, picroside II treatment may inhibit downstream inflammatory factors (e.g., TNF-α and matrix metalloprotein-9 (MMP-9)) via the TLR4-NF-κ B signaling pathway, alleviate cerebral edema, and improve brain function [19].”
Sharma, A., Bhattacharyya, D., Sharma, S., & Chauhan, R. S. (2021) · Genomics · doi:10.1016/j.ygeno.2021.07.024 · Cited by 10 · see citing works
Neutrophilic Lung Inflammation Suppressed by Picroside II Is Associated with TGF-<i>β</i>Signaling
Noh, S., Ahn, K.-S., Oh, S.-R., Kim, K. H., & Joo, M. (2015) · Evidence-Based Complementary and Alternative Medicine · doi:10.1155/2015/897272 · Cited by 10 · cited 3× · see citing works
“7 cells [71].”
InfluentialPiao, X., Sui, X., Liu, B., Cui, T., & Qi, Z. (2021) · BioMed Research International · doi:10.1155/2021/9945149 · Cited by 10 · cited 3× · see citing works
“Picroside II attenuates severe acute pancreatitis (SAP)-induced hepatocyte injury through its antioxidant and anti-inflammatory effects by modulating the JAK2/STAT3 signaling pathway [65].”
InfluentialLi, T., Zheng, Y., Fu, F., Ji, H., Chen, X., Zhao, Y., Zhao, D., Li, N., & Zhang, L. (2011) · Xenobiotica · doi:10.3109/00498254.2011.573018 · Cited by 9 · cited 2× · see citing works
“And the sequence of glucosylation activity of picroside II liver microsomes was rats > mice > humans > dogs [29] (see Figure 2).”
InfluentialWang, F., Xiao, J., Li, M., He, Q., Wang, X., Pan, Z., Li, S., Wang, H., & Zhou, C. (2024) · PLOS ONE · doi:10.1371/journal.pone.0308731 · Cited by 9 · cited 2× · see citing works
“Wang et al. [57] found that picroside II (:25 mg/kg and 50 mg/kg in OA mouse model; 20 µ M and 50 µ M in cellular experiments) inhibited LPS-induced chondrocyte pyroptosis and attenuated osteoarthritis progression in OA mice by regulating the MAPK/NF-κ B/NLRP3 signaling pathway.”
Wu, Q., Tang, A.-L., Dong, Q., Chen, B., Shi, Y. Y., Xu, X., Chen, W., & Chen, W. (2025) · ACS Nano · doi:10.1021/acsnano.5c09760 · Cited by 9 · see citing works
Chemical components, pharmacological actions, and clinical applications of Rhizoma Picrorhizae
Guo, N., Jin, C., Shen, L., Wu, F., Lin, X., & Feng, Y. (2020) · Phytotherapy Research · doi:10.1002/ptr.6591 · Cited by 8 · cited 3× · see citing works
“It is mainly distributed in India and regions of Sichuan, Yunnan, Tibet, and the Himalayas in China [10,11].”
Optimal therapeutic dose and time window of picroside II in cerebral ischemic injury
Liu, G., Zhao, L., Wang, T., Zhang, M., & Pei, H. (2014) · Neural Regeneration Research · doi:10.4103/1673-5374.139460 · Cited by 8 · cited 1× · see citing works
“Liu et al. [84] demonstrated that intraperitoneal injection of 10 mg/kg picroside II at 1.5–2.0 h after post-CIRI in rats was the optimal dose and timing to achieve therapeutic effect.”
InfluentialGuo, Y., Shen, W., & Du, F. (2011) · PubMed · Cited by 8 · see citing works
Self-citationGao, T., Sheng, T., Zhang, T., et al. (2016) · Journal of Pharmaceutical and Biomedical Analysis · doi:10.1016/j.jpba.2016.06.005 · Cited by 7 · cited 2× · see citing works
“Picroside II is an iridoid glycoside formed via an ester linkage between vanillic acid (4-hydroxy-3-methoxybenzoic acid) and catalpol, an iridoid aglycone [14,20].”
Wu, P., Chang, C., Zhu, G., Zhai, L., Zhang, X., Huan, Q., Gao, Z., Deng, H., Liang, Y., & Xiao, H. (2023) · Drug Design, Development and Therapy · doi:10.2147/dddt.s407339 · Cited by 7 · cited 2× · see citing works
“Wu et al. [60] employed UPLC-QTOF-MS, network pharmacology, and experimental validation to investigate the anti-inflammatory mechanisms of the glucoside fraction of Picrorhiza scrophulariiflora Pennell extract against colitis.”
Li, Y., Wang, L., Chen, Z., & Liu, X. (2019) · Acta Cirurgica Brasileira · doi:10.1590/s0102-865020190110000002 · Cited by 7 · cited 2× · see citing works
“Picroside II exerts antioxidant effects by scavenging free radicals in vivo and alleviating oxidative stress-mediated tissue damage [46,77–80].”
Kexin, J. I. A., Zhi, M. A., ZHANG, Y., Kaihong, X. I. E., Jianan, L. I., Jianzhi, W. U., Jiaorong, Q. U., Fanghong, L. I., & Xiaojiaoyang, L. I. (2024) · Chinese Journal of Natural Medicines · doi:10.1016/s1875-5364(24)60571-6 · Cited by 6 · see citing works
Self-citationEvaluation potential effects of Picroside II on cytochrome P450 enzymes in vitro and in vivo
Zhou, N., Zhu, Y., Hu, M., Zheng, R., Sun, M., Bian, Y., Chen, X., & Li, T. (2023) · Journal of Ethnopharmacology · doi:10.1016/j.jep.2023.116582 · Cited by 5 · cited 5× · see citing works
“Zhou et al. [28] used specific probe substrates to evaluate the effect of picroside II on cytochrome P450 (CYP450) activities in human liver microsomes (0.5–200 µ M) and rat liver microsomes (2.5 mg/kg and 10 mg/kg, i.p., for 7 days).”
InfluentialHepatoprotective activity assessment of amino acids derivatives of picroside I and II
Dong, P., Gao, Z., Yin, X., Li, Z., & Han, H. (2021) · Chemical Biology & Drug Design · doi:10.1111/cbdd.13786 · Cited by 5 · cited 1× · see citing works
“This herb exhibits significant hepatoprotective, anti-inflammatory, antioxidant and immunoregulatory effects, and is widely used in the treatment of hepatitis, fatty liver, cirrhosis and other liver diseases [6,10,12].”
Ren, L., Zhao, Y., Ji, X., Li, W., Jiang, W., Li, Q., Zhu, L., & Luo, Y. (2024) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2024.176391 · Cited by 4 · cited 2× · see citing works
“Ren et al. [101] established a bilateral renal IRI-AKI mouse model and evaluated changes in renal microcirculation (Scr, BUN, Cys-C, KIM-1) and inflammatory responses (TNF-α , IL-6) before and after picroside II treatment.”
Zhao, L., Li, X., Wang, T., Guo, Y., Pang, F., & Chang, C. (2013) · Modern Research in Inflammation · doi:10.4236/mri.2013.23006 · Cited by 4 · cited 1× · see citing works
“…common carotid artery occlusion (BCCAO)-induced cerebral ischemic model using 30 Wistar rats , Zhao et al. identified the optimal regimen of picroside II as 10–20 mg/kg intraperitoneally administered 1.5–2.0 h after ischemia, based on the lowest effective dose and widest therapeutic window [86].”
InfluentialSelf-citationPicroside II disrupts IBDV replication via targeting VP1 polymerase
Zhang, D., Wang, J., Wu, H., & Chen, Q. (2024) · Veterinary Microbiology · doi:10.1016/j.vetmic.2024.110191 · Cited by 3 · cited 1× · see citing works
“Picroside II (5–30 µ M) shows promising anti-infectious bursal disease (IBDV) activity and significantly inhibits IBDV replication in a dose-dependent manner for at least 72 h [112].”
Neuroprotective effect of picroside II in brain injury in mice.
(2016) · PubMed Central · Cited by 2 · see citing works
Yifan, X., Jingfeng, H., Huichuan, Z., Junqian, L., Zhenzhou, J., Lixin, S., Xin, H., Luyong, Z., & Tao, W. (2024) · Toxicology Research · doi:10.1093/toxres/tfae073 · Cited by 1 · cited 2× · see citing works
“Picroside II exerts antioxidant effects by scavenging free radicals in vivo and alleviating oxidative stress-mediated tissue damage [46,77–80].”
Li, S.-G., Wang, T. T., Zhai, L., et al. (2018) · PubMed · doi:10.3760/cma.j.issn.0376-2491.2018.02.013 · Cited by 1 · see citing works
[Protective effect of picroside Ⅱ on the brain tissue through antioxidation in stroke rats].
Zhai, L., Wang, J., Ji, Y., et al. (2018) · PubMed · doi:10.3760/cma.j.issn.0376-2491.2018.45.015 · Cited by 1 · see citing works
[Effect of Picroside II on ERK1/2 Signal Pathway in Cerebral lschemic Injury Rats].
Wang, T., Zhai, L., Zhang, H., Zhao, L., & Guo, Y. (2016) · PubMed · Cited by 1 · see citing works
Self-citationJia, K., Ma, Z., Zhang, Y., Wu, J., Xue, X., Liu, R., Qu, J., Li, F., & Li, X. (2023) · doi:10.22541/au.168259699.91375234/v1
Self-citationNeuroprotective effect of picroside II in brain injury in mice
Wang (2016) · Am. J. Transl. Res.
UnresolvedPicroside II protects against sepsis via suppressing inflammation in mice
Huang (2016) · Am. J. Transl. Res.
UnresolvedEffect of picroside II on the expression of mitochondrial vdac1 after cerebral ischemia/reperfusion in rats
Li (2018) · Zhonghua Yi Xue Za Zhi
UnresolvedProtective effect of picroside II on the brain tissue through antioxidation in stroke rats
Zhai (2018) · Zhonghua Yi Xue Za Zhi
Unresolved
Flagged first, then by citations
4 of the 113 references couldn’t be matched to a known paper.
Cited by
Sorted by citations
Molecular insights of a Unani formulation in targeting fibrosis-associated diseases
Thangaraju, R., Kamlesh, N., Shipin, M., Mitra, T., Kumar, A. H. S. A., Gopinathan, A., Ansari, A. P., Karwasra, R., Karthikeyan, D., Agrawal, P., et al. (2026) · Frontiers in Pharmacology · doi:10.3389/fphar.2026.1816025
Yang, J., Song, W., Chen, K., Deng, J., Wang, A., Xu, P., Pan, H., Wang, K., Bian, Z., Chen, S., et al. (2026) · Phytomedicine · doi:10.1016/j.phymed.2026.158811
- Authors
- Ren, Y., Liu, Z., Wei, L., Wang, Y., Wang, Y., Guo, Y., & Ma, Z.
- Affiliations
- Qingdao University (CN)
- Binzhou Medical University (CN)
- Corresponding author
- Guo, Yunliang
- Ma, Zegang
- Venue
- Pharmaceutics
- Publisher
- MDPI AG
- Published
- 2026-04-17
- Volume
- 18
- Issue
- 4
- Pages
- 499
- ISSN
- 1999-4923 (ISSN-L)
- PMC
- PMC13119822
- OpenAlex
- W7154733172
- Semantic Scholar
- 123faa6fafe082a0cfba57a154b288e4e76f5a12
- Cited by
- 2
- References
- 113
- Citations by year
- 2026: 2
- FWCI
- 7.35
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Licence
- Locations
- Pharmaceutics (publishedVersion, cc-by)
- PubMed (publishedVersion)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
- PubMed Central (submittedVersion, cc-by)
- Funders
- National Natural Science Foundation of China (82371425, 81973501)
- Topics
- Life Sciences › Agricultural and Biological Sciences › Plant Science › Phytochemistry and Biological Activities
- Health Sciences › Medicine › Complementary and alternative medicine › Traditional Chinese Medicine Analysis
- Health Sciences › Medicine › Complementary and alternative medicine › Natural Compounds in Disease Treatment
- Keywords
- picroside II, iridoid glycosides, anti-inflammatory activity, molecular mechanisms of inflammation, pharmacokinetics, safety assessment, traditional Chinese medicine, drug development
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Claims read by deepseek-v4.1-flash under definition version 3 (extract-v3) on 2026-10-12.
Classified by jev-1.13-20260917 (gold-guideline-v0.2) on 2026-10-12.
Cited sources are checked by gpt-6-sol.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
